Abstract
Autoimmunity represents a caveat to the use of dendritic cells (DCs) as adjuvant for human vaccines. We derived DCs from normal BALB/c mice or from mice prone to autoimmunity (NZB × NZW) F1. We allowed DCs to phagocytose apoptotic thymocytes and vaccinated syngeneic animals. All mice developed anti-nuclear and anti-dsDNA Abs. Autoantibodies in normal mice were transient, without clinical or histological features of autoimmunity or tissue involvement. In contrast, autoimmunity was maintained in susceptible mice, which underwent renal failure and precociously died. The data suggest that DC vaccination consistently triggers autoimmune responses. However, clinical autoimmunity develops in susceptible subjects only.
Cite
CITATION STYLE
Bondanza, A., Zimmermann, V. S., Dell’Antonio, G., Dal Cin, E., Capobianco, A., Sabbadini, M. G., … Rovere-Querini, P. (2003). Cutting Edge: Dissociation Between Autoimmune Response and Clinical Disease After Vaccination with Dendritic Cells. The Journal of Immunology, 170(1), 24–27. https://doi.org/10.4049/jimmunol.170.1.24
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.